ArticleFrontiers in pharmacology2021
Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Factors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinion.European journal of drug metabolism and pharmacokinetics · 2026Pooled it
- A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.Clinical pharmacokinetics · 2025Pooled it
- Pharmacokinetics of polymyxin B in different populations: a systematic review.European journal of clinical pharmacology · 2024Pooled it
- Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency.Clinical and translational science · 2024Trial
- Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study.Scientific reports · 2026Article
- A Multi-Center Study of Population Pharmacokinetics of Polymyxin B in Critically Ill Patients.Drug design, development and therapy · 2026Article
- Article
- Optimizing Colistin Sulfate Dosing in Severe Infections: A Population Pharmacokinetic Model-Guided Approach.Drug design, development and therapy · 2026Article
- Can the two-point method based on peak and trough concentrations accurately estimate the area under the curve of polymyxin B? A Monte Carlo simulation study.Frontiers in pharmacology · 2026Article
- A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing.Frontiers in pharmacology · 2026Article
- Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients.Antimicrobial agents and chemotherapy · 2025Article
- Population pharmacokinetics of colistin sulfate in critically ill patients based on NONMEM.Scientific reports · 2025Article
- Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria.Antimicrobial agents and chemotherapy · 2025Article
- The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.The Journal of antimicrobial chemotherapy · 2025Article
- Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentration.Frontiers in pharmacology · 2025Article
- A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- How can polymyxin B be dosed based on current pharmacokinetic knowledge?European journal of clinical pharmacology · 2024Article
- Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections.Frontiers in pharmacology · 2024Article
- Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.Critical care (London, England) · 2023Article
- Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, polymyxin B has been widely used in the treatment of multidrug-resistant Gram-negative pathogen infections. Due to the limited pharmacokinetic/pharmacodynamic data, the optimal dosage regimen for the recently proposed therapeutic target of the area under the concentration-time curve over 24 h in steady state divided by the minimum inhibitory concentration 50-100 mg⋅h/L has not yet been established. Moreover, most studies have focused on critically ill patients, yet there have been no studies in the field of renal transplantation. To optimize the dosage strategy and reduce the risk of toxicity, a population pharmacokinetics model of polymyxin B with the Phoenix NLME program was developed in our study. A total of 151 plasma samples from 50 patients were collected in the present study. Polymyxin B plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry. A one-compartment model adequately described the data, and the clearance and volume of distribution were 1.18 L/h and 12.09 L, respectively. A larger creatinine clearance was associated with increased clearance of polymyxin B (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.